RxDoctor Payments Data

Chun Yiu Chow

Family · Houston, TXNPI 1356971907

Payments from drug & device makers

$2,031in general payments, 2019–2025

Across 84 payments — averaging $24.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$698
  • GSK$180
  • Regeneron Healthcare Solutions, Inc.$169
  • Aurinia Pharma U.S., Inc.$139
  • AstraZeneca$119
  • Johnson & Johnson$87
  • plus $639 from 13 others

What the payments were for

  • Food & beverage$1,96997%
  • Education$623%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,031 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$1,908
Medicare patients
40
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept13$96,523
OtezlaApremilast16$75,189
BenlystaBelimumab11$60,465
Dupixent PenDupilumab14$53,180
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,227
Epinephrine51$8,469
Hydroxychloroquine Sulfate222$6,917
Leflunomide48$4,776
MethotrexateMethotrexate Sodium141$3,088
Lidocaine40$3,015
Gabapentin180$2,639
SymbicortBudesonide/Formoterol Fumarate11$2,610
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate13$2,108
Diclofenac Sodium57$2,101
Ipratropium Bromide103$1,894

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$82$75,18916 claims
GSKBenlysta, Trelegy Ellipta$180$69,69223 claims
AstraZenecaSymbicort$119$2,61011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →